Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

PPM1D mutations confer resistance to venetoclax in pre-leukemic and AML populations

Jules Higue, Zhen Xu, Zhi Han Yeoh, Ing Tiong, Natasha Anstee, Michelle Jahja, Chyn Chua, Giovanna Pomillio, Hai Vu Nguyen, Lucie Rigolot, Véronique De Mas, Eric Delabesse, Christian Recher, Ian Majewski, Andrew Wei

Blood (2025) 146 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2025-1507

Published: 2025

Journal Articles

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

Blood (2025) 146 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2025-1744

Published: 2025

Journal Articles

Hematopoietic architecture drives biological and metabolic heterogeneity and predicts treatment-free remission outcomes in chronic myeloid leukemia

Isabelle De Araujo, Mathilde Marlas, Marie-Laure Nicolau, Inès Vergnolle, Lucie Donaty, Isabelle Luquet, Alban Canali, Lucie Rigolot, Laetitia Largeaud, Eric Delabesse, Véronique De Mas, Leopoldine Lapierre, Sarah Bertoli, Christian Recher, Jean-Emmanuel Sarry, Francoise Huguet, Suzanne Tavitian, Francois Vergez

Blood (2025) 146 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2025-3787

Published: 2025

Journal Articles

Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a dataml registry study.

Christian Recher, Emilie Bérard, Suzanne Tavitian, Thibaut Leguay, Anne Huynh, Edouard Forcade, Alban Canali, Emilie Klein, Audrey Bidet, Eric Delabesse, Véronique De Mas, Audrey Sarry, Madeline Mougenot, Anne Charlotte De Grande, Arnaud Pigneux, Sarah Bertoli, Pierre-Yves Dumas

Blood (2025) 146 (Supplement 1): 450.

https://doi.org/10.1182/blood-2025-450

Published: 2025

Journal Articles

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth-Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carre, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon-Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Herve Dombret, Gunnar Juliusson, Anna Robelius, Sören Lehmann, Martin Jädersten, Lovisa Wennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Mariluz Amigo, Patricia Garcia Ramirez, Claudia Sossa, Juan Manuel Alonso-Dominguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Mueller-Tidow, Claudia Baldus, Jurjen Versluis, Peter Valk, Daniel Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lazarevic, Christian Recher

Blood (2025) 146 (Supplement 1): 991.

https://doi.org/10.1182/blood-2025-991

Published: 2025

Journal Articles

Single-Cell Proteomic Analysis Defines Metabolic Heterogeneity in Response to Venetoclax in AML

Lucille Stuani, Astraea Jager, Ambrine Sahal, Abhishek Koladiya, Jolanda Sarno, Pablo Domizi, Yuxuan Liu, Veronique De Mas, Christian Recher, Francois Vergez, Jean-Emmanuel Sarry, Kara L. Davis

Blood (2022) 140 (Supplement 1): 1028–1029.

https://doi.org/10.1182/blood-2022-171009

Published: 2022

Journal Articles

Association between Megakaryocyte Abnormalities on Bone Marrow Smear and Response to Thrombopoietin Receptor Agonists in Adult Patients with Primary Immune Thrombocytopenia

Ondine Walter, Agnès Ribes, Johanne Germain, Jean-Baptiste Rieu, Thibault Comont, Albertine Plat, Brigitte Rivière, Lauréline Deluche, Lucrecia Delarue, Isabelle Le Goff, Monique Greze, Béatrice Dubourdieu, Odile Beyne-Rauzy, Veronique De Mas, Guillaume Moulis

Blood (2021) 138 (Supplement 1): 3160.

https://doi.org/10.1182/blood-2021-151435

Published: 2021

Journal Articles

Genomics of Hyperleukocytic Acute Myeloid Leukemia

Laetitia Largeaud, Sarah Bertoli, Emilie Berard, Suzanne Tavitian, Muriel Picard, Stephanie Dufrechou, Naïs Prade, Francois Vergez, Jean-Baptiste Rieu, Isabelle Luquet, Audrey Sarry, Francoise Huguet, Jean Ruiz, Veronique De Mas, Eric Delabesse, Christian Recher

Blood (2021) 138 (Supplement 1): 1294.

https://doi.org/10.1182/blood-2021-147497

Published: 2021

Journal Articles

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers

Blood (2020) 136 (6): 698–714.

https://doi.org/10.1182/blood.2019003062

Published: 2020

Includes: Supplemental data

Journal Articles

TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine

Pierre Bories, MD, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Julien Plenecassagnes, Isabelle Luquet, MD, Veronique De Mas, Thomas Filleron, PhD, Manon Cassou, Audrey Sarry, Luc Matthieu Fornecker, Célestine Simand, MD, Sarah Bertoli, MD PhD, Hinrich Gronemeyer, Christian Recher, MD PhD, Eric Delabesse, MD PhD

Blood (2018) 132 (Supplement 1): 2745.

https://doi.org/10.1182/blood-2018-99-117219

Published: 2018

Journal Articles

Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms

Edmond Chiche, Sarah Bonnet, Sarah Bertoli, MD PhD, Andrew T Kuykendall, MD, Lauris Gastaud, Pascal Boulay, Veronique De Mas, Eric Delabesse, MD PhD, Alice Marceau-Renaut, Claude Preudhomme, Anne Murati, David A Sallman, MD, S. Dominique Raynaud, MD, Christian Recher, MD PhD, Norbert Vey, MD PhD, Thomas Cluzeau, MD PhD

Blood (2018) 132 (Supplement 1): 2806.

https://doi.org/10.1182/blood-2018-99-114428

Published: 2018

Journal Articles

Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine

Pierre Bories, MD, Naïs Prade, Bastien Cabarrou, Stéphanie Lagarde, Julien Plenecassagnes, Isabelle Luquet, MD, Veronique De Mas, Thomas Filleron, PhD, Manon Cassou, Audrey Sarry, Luc Matthieu Fornecker, Célestine Simand, MD, Sarah Bertoli, MD PhD, Hinrich Gronemeyer, Christian Recher, MD PhD, Eric Delabesse, MD PhD

Blood (2018) 132 (Supplement 1): 1467.

https://doi.org/10.1182/blood-2018-99-117336

Published: 2018

Journal Articles

Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia

Fabienne de Toni, PhD, Robin L. Perry, MD, Estelle Saland, Mayumi Sugita, MD, Marion David, PhD, François Vergez, VMD, Eric Delabesse, MD, PhD, Véronique De Mas Mansat, PharmD PhD, Cécile Demur, MD, Jason Iacovoni, PhD, Stéphane Manenti, PhD, Gwenn Danet-Desnoyers, Christian Recher, MD PhD, Martin Carroll, MD, Jean-Emmanuel Sarry, PhD

Blood (2013) 122 (21): 1651.

https://doi.org/10.1182/blood.V122.21.1651.1651

Published: 2013

Journal Articles

Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS

Raphael Itzykson, Olivier Kosmider, Thomas Cluzeau, Veronique De Mas, Francois Dreyfus, Bruno Quesnel, MD, PhD, Odile Beyne-Rauzy, Norbert Vey, MD, Veronique Gelsi-Boyer, Sophie Raynaud, Claude Preudhomme, Lionel Ades, MD, Pierre Fenaux, MD, PhD, Michaela Fontenay

Blood (2010) 116 (21): 439.

https://doi.org/10.1182/blood.V116.21.439.439

Published: 2010

Journal Articles

The Receptor Tyrosine Kinase RON Is Constitutively Activated in Acute Myeloid Leukemia and May Represent a New Therapeutic Target.

Camille Fialin, Veronique De Mas, Stephane Manenti, Bernard Payrastre, PhD, Serge Roche, Christian Recher

Blood (2009) 114 (22): 994.

https://doi.org/10.1182/blood.V114.22.994.994

Published: 2009

Journal Articles

TNFα Stimulates NKG2D-Mediated Lytic Activity of Acute Myeloid Leukemic Cells.

Guy Laurent, Fabien Guilloton, Aurelie de Thonel, Christine Jean, Cecile Demur, Veronique De Mas, Anne Quillet-Mary

Blood (2005) 106 (11): 4411.

https://doi.org/10.1182/blood.V106.11.4411.4411

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

PPM1D mutations confer resistance to venetoclax in pre-leukemic and AML populations

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

Hematopoietic architecture drives biological and metabolic heterogeneity and predicts treatment-free remission outcomes in chronic myeloid leukemia

Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a dataml registry study.

The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy

Single-Cell Proteomic Analysis Defines Metabolic Heterogeneity in Response to Venetoclax in AML

Association between Megakaryocyte Abnormalities on Bone Marrow Smear and Response to Thrombopoietin Receptor Agonists in Adult Patients with Primary Immune Thrombocytopenia

Genomics of Hyperleukocytic Acute Myeloid Leukemia

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers

TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine

Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms

Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine

Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia

Presence of TET2 Mutation Predicts A Higher Response Rate to Azacitidine In MDS and AML Post MDS

The Receptor Tyrosine Kinase RON Is Constitutively Activated in Acute Myeloid Leukemia and May Represent a New Therapeutic Target.

TNFα Stimulates NKG2D-Mediated Lytic Activity of Acute Myeloid Leukemic Cells.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only